Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Genmab announced worldwide net trade sales of DARZALEX totaled USD 4,239 million in the third quarter of 2026, as reported by partner Johnson & Johnson. Sales split into USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world, including the subcutaneous DARZALEX FASPRO product.
Key figures
- Revenue
- $4,239 million
- Us net sales usd m
- 2528
- Row net sales usd m
- 1711
- Darzalex q3 worldwide net sales usd m
- 4239
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.